Utah Medical Products Inc. releases its Q3 2026 results, emphasizing growth in the surgical and medical instruments sector amid industry competition.
| Name | UTAH MEDICAL PRODUCTS INC |
|---|---|
| CIK | 0000706698 |
| Tickers | UTMD |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 3841 Surgical & Medical Instruments & Apparatus |
| EIN | 870342734 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | UT UT |
| Phone | 8015215301 |
| Website | — |
| Investor website | — |
| Owner org | 08 Industrial Applications and Services |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Utah Medical Products Inc. releases its Q3 2026 results, emphasizing growth in the surgical and medical instruments sector amid industry competition.
Utah Medical Products Inc. increases its quarterly cash dividend to $0.315 per share, reflecting a 1.6% rise, effective January 5, 2027.
Utah Medical Products Inc. completed its tender offer, purchasing 327,740 shares at $75 each, signaling a strong commitment to shareholder value.
Utah Medical Products Inc. reports Q3 2026 results, revealing a revenue decline due to lost customers in the surgical and medical instruments sector.
849 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-13 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001096906-26-001742 | 001-12575 | 261552008 | 34 | 2810592 | 1 | 1 | |
| 2026-11-03 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 8.01,9.01 | 0001096906-26-001664 | 001-12575 | 261515830 | 34 | 146901 | 1 | 1 |
| 2026-10-29 | 4 | PRIMARY DOCUMENT | 0001733614-26-000005 | 4859 | ||||||
| 2026-10-29 | SC TO-I/A | SCHEDULE TO-I/A | 0001096906-26-001646 | 005-34115 | 261500250 | 34 | 12694 | |||
| 2026-10-22 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-26-001602 | 001-12575 | 261478623 | 34 | 342974 | 1 | 1 |
| 2026-10-05 | SC TO-I/A | SCHEDULE TO-I/A | 0001096906-26-001502 | 005-34115 | 261439439 | 34 | 9253 | |||
| 2026-09-29 | SC TO-I/A | SCHEDULE TO-I/A | 0001096906-26-001481 | 005-34115 | 261424598 | 34 | 500065 | 1 | 1 | |
| 2026-09-25 | SC TO-C | SCHEDULE TO-C | 0001096906-26-001447 | 005-34115 | 261408412 | 34 | 13125 | |||
| 2026-09-24 | SC TO-C | SCHEDULE TO-C | 0001096906-26-001439 | 005-34115 | 261405363 | 34 | 18285 | |||
| 2026-09-24 | SC TO-I | SC TO-I | 0001096906-26-001428 | 005-34115 | 261402033 | 34 | 831028 | 1 | 1 | |
| 2026-09-17 | SC TO-C | FORM SC TO-C | 0001096906-26-001373 | 005-34115 | 261384785 | 34 | 17204 | |||
| 2026-08-31 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 7.01 | 0001096906-26-001326 | 001-12575 | 261345141 | 34 | 149701 | 1 | 1 |
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001015079-26-000089 | 005-34115 | 261279409 | 34 | 10037 | |||
| 2026-08-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001037389-26-000058 | 005-34115 | 261273890 | 34 | 9375 | |||
| 2026-08-12 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001096906-26-001210 | 001-12575 | 261266706 | 34 | 2381103 | 1 | 1 | |
| 2026-07-23 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-26-001112 | 001-12575 | 261196754 | 34 | 283474 | 1 | 1 |
| 2026-07-01 | 4 | PRIMARY DOCUMENT | 0001733614-26-000003 | 4777 | ||||||
| 2026-05-29 | 4 | PRIMARY DOCUMENT | 0001733614-26-000001 | 4503 | ||||||
| 2026-05-27 | SD | UTAH MEDICAL FORM SD | 0001096906-26-000865 | 001-12575 | 261024945 | 34 | 13046 | |||
| 2026-05-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001015079-26-000060 | 005-34115 | 26980807 | 34 | 6805 | |||
| 2026-05-12 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001096906-26-000767 | 001-12575 | 26968209 | 34 | 2015432 | 1 | 1 | |
| 2026-05-04 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 5.07 | 0001096906-26-000685 | 001-12575 | 26936960 | 34 | 141385 | 1 | 1 |
| 2026-04-23 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-26-000602 | 001-12575 | 26888299 | 34 | 211799 | 1 | 1 |
| 2026-04-02 | DEF 14A | PROXY STATEMENT | 0001096906-26-000477 | 001-12575 | 26835033 | 34 | 527931 | |||
| 2026-03-27 | 10-K | UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING | 0001096906-26-000395 | 001-12575 | 26808676 | 34 | 5933730 | 1 | 1 | |
| 2026-03-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-002547 | 005-34115 | 26805120 | 34 | 7106 | |||
| 2026-01-29 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-26-000161 | 001-12575 | 26577387 | 34 | 291931 | 1 | 1 |
| 2025-12-18 | 3 | PRIMARY DOCUMENT | 0001733614-25-000007 | 4098 | ||||||
| 2025-11-25 | 4 | PRIMARY DOCUMENT | 0001733614-25-000004 | 5344 | ||||||
| 2025-11-14 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001096906-25-001839 | 001-12575 | 251484458 | 34 | 2462545 | 1 | 1 | |
| 2025-11-04 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 5.02,8.01,9.01 | 0001096906-25-001733 | 001-12575 | 251447837 | 34 | 151911 | 1 | 1 |
| 2025-10-23 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-25-001708 | 001-12575 | 251412823 | 34 | 288482 | 1 | 1 |
| 2025-09-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001041062-25-000177 | 005-34115 | 251297361 | 34 | 6708 | |||
| 2025-09-05 | 4 | PRIMARY DOCUMENT | 0001733614-25-000002 | 4432 | ||||||
| 2025-08-26 | 4 | PRIMARY DOCUMENT | 0001733614-25-000001 | 4707 | ||||||
| 2025-08-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001041062-25-000148 | 005-34115 | 251207177 | 34 | 6716 | |||
| 2025-08-12 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001096906-25-001281 | 001-12575 | 251206401 | 34 | 2490596 | 1 | 1 | |
| 2025-07-24 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-25-001180 | 001-12575 | 251146282 | 34 | 292311 | 1 | 1 |
| 2025-07-17 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-003275 | 005-34115 | 251132455 | 34 | 10708 | |||
| 2025-07-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000354204-25-001052 | 005-34115 | 251124755 | 34 | 8604 | |||
| 2025-05-28 | SD | UTAH MEDICAL PRODUCTS, INC. FORM SD | 0001096906-25-000893 | 001-12575 | 25993761 | 34 | 12981 | |||
| 2025-05-15 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001096906-25-000816 | 001-12575 | 25951694 | 34 | 2109530 | 1 | 1 | |
| 2025-05-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001041062-25-000110 | 005-34115 | 25946996 | 34 | 6639 | |||
| 2025-05-05 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 5.07 | 0001096906-25-000679 | 001-12575 | 25913850 | 34 | 149170 | 1 | 1 |
| 2025-04-29 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-25-000625 | 001-12575 | 25885858 | 34 | 215983 | 1 | 1 |
| 2025-04-04 | DEF 14A | UTAH MEDICAL PRODUCTS, INC. - DEF 14A | 0001096906-25-000427 | 001-12575 | 25815769 | 34 | 467860 | |||
| 2025-03-26 | 10-K | UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING | 0001096906-25-000308 | 001-12575 | 25774277 | 34 | 5886429 | 1 | 1 | |
| 2025-02-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-25-001340 | 005-34115 | 25592347 | 34 | 11637 | |||
| 2025-01-28 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-25-000095 | 001-12575 | 25563733 | 34 | 297344 | 1 | 1 |
| 2025-01-08 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-000036 | 005-34115 | 25516902 | 34 | 11251 | |||
| 2024-11-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001037389-24-000117 | 005-34115 | 241453781 | 34 | 9170 | |||
| 2024-11-12 | SC 13G/A | UnitedStates_13G__UtahMedica.txt | 0000932471-24-001311 | 005-34115 | 241450372 | 34 | 6427 | |||
| 2024-11-12 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-24-000022 | 001-12575 | 241447238 | 34 | 2276533 | 1 | 1 | |
| 2024-11-12 | SC 13G/A | filing.txt | 0000315066-24-002914 | 005-34115 | 241444990 | 34 | 8092 | |||
| 2024-11-12 | 3 | PRIMARY DOCUMENT | 0001733614-24-000004 | 4697 | ||||||
| 2024-11-08 | 4 | PRIMARY DOCUMENT | 0001733614-24-000003 | 5265 | ||||||
| 2024-11-05 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 5.02,8.01,9.01 | 0001096906-24-002072 | 001-12575 | 241427028 | 34 | 159220 | 1 | 1 |
| 2024-11-04 | SC 13G/A | UnitedStates_13G__UtahMedica.txt | 0000932471-24-000745 | 005-34115 | 241422524 | 34 | 5501 | |||
| 2024-10-31 | SC 13G | SEC SCHEDULE 13G | 0000354204-24-004750 | 005-34115 | 241413836 | 34 | 19165 | |||
| 2024-10-29 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-24-002035 | 001-12575 | 241405097 | 34 | 284882 | 1 | 1 |
| 2024-08-09 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-24-000018 | 001-12575 | 241192595 | 34 | 2281635 | 1 | 1 | |
| 2024-07-25 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.01,9.01 | 0001096906-24-001590 | 001-12575 | 241141348 | 34 | 296346 | 1 | 1 |
| 2024-07-22 | 4 | PRIMARY DOCUMENT | 0001733614-24-000002 | 4346 | ||||||
| 2024-05-31 | SD | UTAH MEDICAL PRODUCT - FORM SD | 0001096906-24-001277 | 001-12575 | 241008627 | 34 | 12984 | |||
| 2024-05-17 | 4 | PRIMARY DOCUMENT | 0001733614-24-000001 | 4620 | ||||||
| 2024-05-10 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-24-000015 | 001-12575 | 24933485 | 34 | 1924843 | 1 | 1 | |
| 2024-05-06 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 5.07 | 0001096906-24-001026 | 001-12575 | 24917140 | 34 | 143785 | 1 | 1 |
| 2024-04-25 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.01,9.01 | 0001096906-24-000934 | 001-12575 | 24875518 | 34 | 217782 | 1 | 1 |
| 2024-04-15 | DEFA14A | UTAH MEDICAL PRODUCTS, INC. FORM DEFA14A | 0001096906-24-000826 | 001-12575 | 24844359 | 34 | 18227 | |||
| 2024-04-10 | DEF 14A | UTAH MEDICAL FORM DEF 14A | 0001096906-24-000764 | 001-12575 | 24834055 | 34 | 381332 | |||
| 2024-03-26 | 10-K | UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING | 0001811884-24-000009 | 001-12575 | 24782128 | 34 | 5524762 | 1 | 1 | |
| 2024-02-14 | SC 13G/A | utmd13gadec23.txt | 0001897612-24-001141 | 005-34115 | 34 | 6391 | ||||
| 2024-02-13 | SC 13G/A | utmd-13g_20231231.txt | 0001037389-24-000065 | 005-34115 | 24623415 | 34 | 13256 | |||
| 2024-02-09 | SC 13G/A | filing.txt | 0000315066-24-001569 | 005-34115 | 24612685 | 34 | 8203 | |||
| 2024-01-30 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-24-000127 | 001-12575 | 24577568 | 34 | 276758 | 1 | 1 |
| 2024-01-29 | SC 13G/A | us9174881089_012924.txt | 0001086364-24-005552 | 005-34115 | 24574885 | 34 | 13258 | |||
| 2023-12-26 | 4 | PRIMARY DOCUMENT | 0001733614-23-000005 | 5271 | ||||||
| 2023-11-13 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-23-000021 | 001-12575 | 231396342 | 34 | 2208008 | 1 | 1 | |
| 2023-10-31 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 8.01,9.01 | 0001096906-23-002066 | 001-12575 | 231363230 | 34 | 153637 | 1 | 1 |
| 2023-10-26 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-23-002058 | 001-12575 | 231349944 | 34 | 287351 | 1 | 1 |
| 2023-08-11 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-23-000017 | 001-12575 | 231162378 | 34 | 2193522 | 1 | 1 | |
| 2023-07-25 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-23-001449 | 001-12575 | 231108147 | 34 | 315970 | 1 | 1 |
| 2023-07-14 | S-8 | UTAH MEDICAL PRODUCTS, INC. - S-8 | 0001096906-23-001418 | 333-273261 | 231089637 | 33 | 201369 | |||
| 2023-06-20 | 4 | PRIMARY DOCUMENT | 0001733614-23-000004 | 4241 | ||||||
| 2023-06-14 | 144 | xsl144X01/primary_doc.xml | 0001959173-23-001851 | 001-12575 | 231013084 | 33 | 4466 | |||
| 2023-05-30 | SD | UTAH MEDICAL PRODUCT - FORM SD | 0001096906-23-001202 | 001-12575 | 23974424 | 34 | 13054 | |||
| 2023-05-19 | 4 | PRIMARY DOCUMENT | 0001733614-23-000003 | 4515 | ||||||
| 2023-05-18 | 144 | xsl144X01/primary_doc.xml | 0001949846-23-000088 | 001-12575 | 23936629 | 33 | 3966 | |||
| 2023-05-08 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 5.07 | 0001096906-23-000990 | 001-12575 | 23897502 | 34 | 153123 | 1 | 1 |
| 2023-05-05 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-23-000013 | 001-12575 | 23892363 | 34 | 1789631 | 1 | 1 | |
| 2023-04-25 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-23-000901 | 001-12575 | 23844778 | 34 | 215366 | 1 | 1 |
| 2023-04-12 | DEFA14A | UTAH MEDICAL PRODUCTS, INC. FORM DEF-A-14A | 0001096906-23-000785 | 001-12575 | 23815390 | 34 | 119136 | |||
| 2023-04-04 | DEF 14A | PROXY STATEMENT | 0001096906-23-000725 | 001-12575 | 23795859 | 34 | 580459 | |||
| 2023-03-28 | 10-K/A | UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING | 0001811884-23-000008 | 001-12575 | 23769882 | 34 | 5489337 | 1 | 1 | |
| 2023-03-27 | 10-K | UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING | 0001811884-23-000004 | 001-12575 | 23764785 | 34 | 5518957 | 1 | 1 | |
| 2023-03-17 | 4 | PRIMARY DOCUMENT | 0001733614-23-000002 | 4481 | ||||||
| 2023-02-14 | SC 13G | utmd13gdec22.txt | 0001897612-23-000640 | 005-34115 | 34 | 9378 | ||||
| 2023-02-13 | SC 13G/A | utmd-13g_20221231.txt | 0001037389-23-000057 | 005-34115 | 23615838 | 34 | 13157 | |||
| 2023-02-09 | 4 | PRIMARY DOCUMENT | 0001733614-23-000001 | 4027 | ||||||
| 2023-02-09 | SC 13G/A | filing.txt | 0000315066-23-002111 | 005-34115 | 23605141 | 34 | 8040 | |||
| 2023-02-09 | SC 13G/A | SCHEDULE 13G/A | 0001104659-23-017211 | 005-34115 | 23604513 | 34 | 12837 | |||
| 2023-02-01 | SC 13G/A | us9174881089_020123.txt | 0001306550-23-006483 | 005-34115 | 23577562 | 34 | 12978 | |||
| 2023-01-31 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-23-000240 | 001-12575 | 23572871 | 34 | 278962 | 1 | 1 |
| 2022-12-06 | 4 | PRIMARY DOCUMENT | 0001733614-22-000009 | 8111 | ||||||
| 2022-11-21 | 4 | PRIMARY DOCUMENT | 0001733614-22-000008 | 4484 | ||||||
| 2022-11-17 | 4 | PRIMARY DOCUMENT | 0001733614-22-000007 | 4481 | ||||||
| 2022-11-15 | 4 | PRIMARY DOCUMENT | 0001733614-22-000006 | 4482 | ||||||
| 2022-11-10 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-22-000015 | 001-12575 | 221375710 | 34 | 2139841 | 1 | 1 | |
| 2022-11-03 | 4 | PRIMARY DOCUMENT | 0001733614-22-000005 | 4209 | ||||||
| 2022-11-01 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 8.01,9.01 | 0001096906-22-002609 | 001-12575 | 221349635 | 34 | 154173 | 1 | 1 |
| 2022-10-25 | 4 | PRIMARY DOCUMENT | 0001733614-22-000004 | 5137 | ||||||
| 2022-10-25 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-22-002547 | 001-12575 | 221329030 | 34 | 306652 | 1 | 1 |
| 2022-08-12 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-22-000012 | 001-12575 | 221159135 | 34 | 2137836 | 1 | 1 | |
| 2022-08-10 | SC 13G/A | utmd13gajul22.txt | 0000080255-22-002459 | 005-34115 | 34 | 9533 | ||||
| 2022-07-28 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-22-001712 | 001-12575 | 221112145 | 34 | 318217 | 1 | 1 |
| 2022-06-27 | 4 | PRIMARY DOCUMENT | 0001733614-22-000003 | 4484 | ||||||
| 2022-06-10 | SC 13G/A | utmd13gamay22.txt | 0000080255-22-002351 | 005-34115 | 34 | 9309 | ||||
| 2022-05-31 | SD | UTAH MEDICAL PRODUCTS, INC. - FORM SD | 0001096906-22-001309 | 001-12575 | 22983378 | 34 | 11643 | |||
| 2022-05-11 | 4 | PRIMARY DOCUMENT | 0001733614-22-000002 | 4028 | ||||||
| 2022-05-11 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-22-000008 | 001-12575 | 22912801 | 34 | 1733730 | 1 | 1 | |
| 2022-05-09 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 5.07 | 0001096906-22-001059 | 001-12575 | 22904268 | 34 | 165863 | 1 | 1 |
| 2022-04-27 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-22-000948 | 001-12575 | 22855618 | 34 | 229936 | 1 | 1 |
| 2022-04-13 | DEF 14A | PROXY STATEMENT | 0001096906-22-000827 | 001-12575 | 22825074 | 34 | 495196 | |||
| 2022-03-25 | 10-K | UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING | 0001811884-22-000004 | 001-12575 | 22771226 | 34 | 5457961 | 1 | 1 | |
| 2022-02-14 | SC 13G/A | utmd13gadec21.txt | 0000080255-22-001907 | 005-34115 | 34 | 9328 | ||||
| 2022-02-11 | SC 13G/A | utmd-13g_20211231.txt | 0001037389-22-000199 | 005-34115 | 22620393 | 34 | 13155 | |||
| 2022-02-10 | 4 | PRIMARY DOCUMENT | 0001733614-22-000001 | 4025 | ||||||
| 2022-02-10 | SC 13G/A | SCHEDULE 13G/A | 0001104659-22-018812 | 005-34115 | 22611055 | 34 | 12832 | |||
| 2022-02-09 | SC 13G/A | filing.txt | 0000315066-22-001192 | 005-34115 | 22604670 | 34 | 8583 | |||
| 2022-02-08 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 8.01,9.01 | 0001096906-22-000265 | 001-12575 | 22600478 | 34 | 189254 | 1 | 1 |
| 2022-02-02 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-22-000245 | 001-12575 | 22580706 | 34 | 366249 | 1 | 1 |
| 2022-02-01 | SC 13G/A | us9174881089_013122.txt | 0000834237-22-003967 | 005-34115 | 22575655 | 34 | 12978 | |||
| 2021-12-13 | 4 | PRIMARY DOCUMENT | 0001733614-21-000011 | 6646 | ||||||
| 2021-11-26 | 4 | PRIMARY DOCUMENT | 0001733614-21-000010 | 5886 | ||||||
| 2021-11-23 | 4 | PRIMARY DOCUMENT | 0001733614-21-000009 | 4430 | ||||||
| 2021-11-18 | 4 | PRIMARY DOCUMENT | 0001733614-21-000008 | 5499 | ||||||
| 2021-11-12 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-21-000016 | 001-12575 | 211401289 | 34 | 2128320 | 1 | 1 | |
| 2021-11-02 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 8.01,9.01 | 0001096906-21-002618 | 001-12575 | 211370057 | 34 | 193021 | 1 | 1 |
| 2021-10-28 | 4 | PRIMARY DOCUMENT | 0001733614-21-000007 | 7497 | ||||||
| 2021-10-28 | 4 | PRIMARY DOCUMENT | 0001733614-21-000006 | 11989 | ||||||
| 2021-10-26 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-21-002587 | 001-12575 | 211347890 | 34 | 383695 | 1 | 1 |
| 2021-08-30 | 4 | PRIMARY DOCUMENT | 0001733614-21-000005 | 5492 | ||||||
| 2021-08-27 | 4 | PRIMARY DOCUMENT | 0001733614-21-000004 | 4022 | ||||||
| 2021-08-06 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-21-000012 | 001-12575 | 211151532 | 34 | 2411450 | 1 | 1 | |
| 2021-07-22 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001096906-21-001665 | 001-12575 | 211106798 | 34 | 332095 | 1 | 1 |
| 2021-05-26 | SD | UTAH MEDICAL FORM SD | 0001096906-21-001296 | 001-12575 | 21965403 | 34 | 12978 | |||
| 2021-05-11 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-21-000008 | 001-12575 | 21910293 | 34 | 2004208 | 1 | 1 | |
| 2021-05-07 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 5.07 | 0001096906-21-001059 | 001-12575 | 21904048 | 34 | 178168 | 1 | 1 |
| 2021-04-23 | 8-K | UTAH MEDICAL FORM 8-K | 2.02,9.01 | 0001096906-21-000840 | 001-12575 | 21845975 | 34 | 83507 | ||
| 2021-04-12 | DEF 14A | PROXY STATEMENT | 0001096906-21-000735 | 001-12575 | 21819090 | 34 | 465317 | |||
| 2021-03-26 | 10-K | UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING | 0001811884-21-000004 | 001-12575 | 21775805 | 34 | 5564497 | 1 | 1 | |
| 2021-03-12 | 4 | PRIMARY DOCUMENT | 0001733614-21-000003 | 4483 | ||||||
| 2021-03-10 | 4 | PRIMARY DOCUMENT | 0001733614-21-000002 | 4024 | ||||||
| 2021-03-01 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 1.02 | 0001096906-21-000377 | 001-12575 | 21697974 | 34 | 180451 | 1 | 1 |
| 2021-02-16 | SC 13G/A | utmd13gadec20.txt | 0000080255-21-001001 | 005-34115 | 34 | 9327 | ||||
| 2021-02-11 | SC 13G/A | utmd-13g_20201231.txt | 0001037389-21-000313 | 005-34115 | 21618744 | 34 | 13155 | |||
| 2021-02-10 | SC 13G | SCHEDULE 13G | 0001104659-21-019329 | 005-34115 | 21612248 | 34 | 13658 | |||
| 2021-02-09 | 4 | PRIMARY DOCUMENT | 0001733614-21-000001 | 4027 | ||||||
| 2021-02-08 | SC 13G/A | filing.txt | 0000315066-21-001343 | 005-34115 | 21599872 | 34 | 8545 | |||
| 2021-02-01 | SC 13G/A | us9174881089_013121.txt | 0000834237-21-005553 | 005-34115 | 21574540 | 34 | 12959 | |||
| 2021-01-28 | 8-K | UTAH MEDICAL 8-K | 2.02,9.01 | 0001096906-21-000171 | 001-12575 | 21565103 | 34 | 168911 | ||
| 2020-11-09 | 10-Q/A | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-20-000018 | 001-12575 | 201298798 | 34 | 2382023 | 1 | 1 | |
| 2020-11-06 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-20-000015 | 001-12575 | 201294243 | 34 | 2375850 | 1 | 1 | |
| 2020-11-03 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 8.01,9.01 | 0001096906-20-000150 | 001-12575 | 201284478 | 34 | 157918 | 1 | 1 |
| 2020-10-27 | 8-K | UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING | 2.02,9.01 | 0001445866-20-001623 | 001-12575 | 201264324 | 34 | 299967 | 1 | 1 |
| 2020-08-10 | 8-K | UTAH MEDICAL 8-K | 5.07 | 0001445866-20-001137 | 001-12575 | 201088448 | 34 | 13434 | ||
| 2020-08-07 | 10-Q | UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING | 0001811884-20-000011 | 001-12575 | 201084927 | 34 | 2320661 | 1 | 1 | |
| 2020-07-28 | 8-K | UTAH MEDICAL 8-K | 2.02,9.01 | 0001445866-20-001050 | 001-12575 | 201053006 | 34 | 102871 | ||
| 2020-07-14 | DEF 14A | PROXY STATEMENT | 0001445866-20-001001 | 001-12575 | 201026533 | 34 | 458221 | |||
| 2020-06-09 | 4 | PRIMARY DOCUMENT | 0001733614-20-000012 | 4421 | ||||||
| 2020-06-05 | 4 | PRIMARY DOCUMENT | 0001733614-20-000011 | 6009 | ||||||
| 2020-06-05 | 4 | PRIMARY DOCUMENT | 0001733614-20-000010 | 4025 | ||||||
| 2020-06-04 | 4 | PRIMARY DOCUMENT | 0001733614-20-000009 | 4030 | ||||||
| 2020-05-29 | SD | UTAH MEDICAL PRODUCTS INC - FORM SD | 0001445866-20-000764 | 001-12575 | 20928647 | 34 | 13258 | |||
| 2020-05-28 | 4 | PRIMARY DOCUMENT | 0001733614-20-000008 | 4024 | ||||||
| 2020-05-28 | 4 | PRIMARY DOCUMENT | 0001733614-20-000007 | 4485 | ||||||
| 2020-05-27 | 4 | PRIMARY DOCUMENT | 0001733614-20-000006 | 4023 | ||||||
| 2020-05-22 | 4 | PRIMARY DOCUMENT | 0001733614-20-000005 | 4027 | ||||||
| 2020-05-19 | 4 | PRIMARY DOCUMENT | 0001733614-20-000004 | 4029 | ||||||
| 2020-05-13 | 4 | PRIMARY DOCUMENT | 0001733614-20-000003 | 4482 | ||||||
| 2020-05-11 | 4 | PRIMARY DOCUMENT | 0001733614-20-000002 | 4483 | ||||||
| 2020-05-08 | 10-Q | UTAH MEDICAL 10-Q | 0001445866-20-000588 | 001-12575 | 20860119 | 34 | 1534726 | 1 | ||
| 2020-04-23 | 8-K | UTAH MEDICAL 8-K | 2.02 | 0001445866-20-000449 | 001-12575 | 20810124 | 34 | 81068 | ||
| 2020-03-31 | 10-K/A | 10KA1 | 0001096906-20-000131 | 001-12575 | 20761329 | 34 | 423709 | |||
| 2020-03-24 | 8-K | 8K | 8.01,9.01 | 0001096906-20-000117 | 001-12575 | 20736202 | 34 | 26045 | ||
| 2020-03-16 | 10-K | 10K | 0001096906-20-000111 | 001-12575 | 20718200 | 34 | 5094893 | 1 | ||
| 2020-02-21 | 4 | PRIMARY DOCUMENT | 0001733614-20-000001 | 4028 | ||||||
| 2020-02-14 | SC 13G/A | utmd13gadec19.txt | 0000080255-20-001008 | 005-34115 | 34 | 9288 | ||||
| 2020-02-13 | SC 13G/A | utmd-13g_20191231.txt | 0001037389-20-000285 | 005-34115 | 20609124 | 34 | 13164 | |||
| 2020-02-07 | SC 13G/A | filing.txt | 0000315066-20-001225 | 005-34115 | 20585950 | 34 | 8488 | |||
| 2020-02-07 | SC 13G | us9174881089_020620.txt | 0000834237-20-008012 | 005-34115 | 20584657 | 34 | 12950 | |||
| 2020-01-30 | 8-K | 8-K | 2.02,9.01 | 0001096906-20-000051 | 001-12575 | 20561213 | 34 | 201368 | ||
| 2019-12-13 | 4 | PRIMARY DOCUMENT | 0001733614-19-000011 | 6004 | ||||||
| 2019-11-29 | 4 | PRIMARY DOCUMENT | 0001733614-19-000010 | 4420 | ||||||
| 2019-11-19 | 4 | PRIMARY DOCUMENT | 0001733614-19-000009 | 4028 | ||||||
| 2019-11-13 | 4 | PRIMARY DOCUMENT | 0001733614-19-000008 | 4023 | ||||||
| 2019-11-12 | 4 | PRIMARY DOCUMENT | 0001733614-19-000007 | 4028 | ||||||
| 2019-11-07 | 10-Q | 10Q | 0001096906-19-000361 | 001-12575 | 191201013 | 34 | 2266771 | 1 | ||
| 2019-11-07 | 4 | PRIMARY DOCUMENT | 0001733614-19-000006 | 4421 | ||||||
| 2019-11-07 | 4 | PRIMARY DOCUMENT | 0001733614-19-000005 | 4208 | ||||||
| 2019-11-05 | 8-K | 8K | 8.01,9.01 | 0001096906-19-000353 | 001-12575 | 191192393 | 34 | 24130 | ||
| 2019-10-24 | 8-K | 8K | 2.02,9.01 | 0001096906-19-000350 | 001-12575 | 191165891 | 34 | 226512 | ||
| 2019-09-13 | UPLOAD | filename1.pdf | 0000000000-19-013576 | 39303 | ||||||
| 2019-09-10 | CORRESP | filename1.htm | 0001096906-19-000326 | 156519 | ||||||
| 2019-09-10 | UPLOAD | filename1.pdf | 0000000000-19-013408 | 43926 | ||||||
| 2019-08-09 | 10-Q | 10Q | 0001096906-19-000278 | 001-12575 | 191010958 | 34 | 2205921 | 1 | ||
| 2019-07-30 | 8-K | 8K | 2.02,9.01 | 0001096906-19-000270 | 001-12575 | 19984315 | 34 | 210246 | ||
| 2019-06-07 | SC 13G/A | r13gautahmed.htm | 0001207017-19-000038 | 005-34115 | 19885918 | 34 | 5730 | |||
| 2019-05-31 | SD | FORM SD | 0001096906-19-000228 | 001-12575 | 19869295 | 34 | 17714 | |||
| 2019-05-09 | 10-Q | 10Q | 0001096906-19-000172 | 001-12575 | 19808037 | 34 | 1809540 | 1 | ||
| 2019-05-06 | 8-K | 8K | 5.07 | 0001096906-19-000161 | 001-12575 | 19798724 | 34 | 21636 | ||
| 2019-04-25 | 8-K | 8K | 2.02,9.01 | 0001096906-19-000154 | 001-12575 | 19766469 | 34 | 195209 | ||
| 2019-04-05 | DEF 14A | DEF 14A | 0001096906-19-000126 | 001-12575 | 19733125 | 34 | 935600 | |||
| 2019-03-14 | 10-K | 10K | 0001096906-19-000100 | 001-12575 | 19681408 | 34 | 5800631 | 1 | ||
| 2019-02-28 | 4 | PRIMARY DOCUMENT | 0001733614-19-000003 | 5489 | ||||||
| 2019-02-22 | 4 | PRIMARY DOCUMENT | 0001733614-19-000002 | 4021 | ||||||
| 2019-02-15 | 4 | PRIMARY DOCUMENT | 0001733614-19-000001 | 6961 | ||||||
| 2019-02-14 | SC 13G/A | utmd13gadec18.txt | 0000080255-19-002389 | 005-34115 | 34 | 9287 | ||||
| 2019-02-13 | SC 13G/A | utmd-13g_20181231.txt | 0001037389-19-000255 | 005-34115 | 19595780 | 34 | 13099 | |||
| 2019-02-13 | SC 13G/A | filing.txt | 0000315066-19-001376 | 005-34115 | 19595216 | 34 | 8494 | |||
| 2019-02-13 | 8-K | 8K | 2.01,9.01 | 0001096906-19-000061 | 001-12575 | 19592859 | 34 | 1720432 | ||
| 2019-02-12 | SC 13G | r13gutahmed.htm | 0001207017-19-000002 | 005-34115 | 19587866 | 34 | 5782 | |||
| 2019-02-11 | SC 13G/A | us9174881089_021119.txt | 0000215457-19-007484 | 005-34115 | 19585692 | 34 | 12126 | |||
| 2019-02-08 | SC 13G | us9174881089_020719.txt | 0000215457-19-006729 | 005-34115 | 19576535 | 34 | 12996 | |||
| 2019-01-31 | 8-K | 8-K | 2.02,9.01 | 0001096906-19-000047 | 001-12575 | 19555707 | 34 | 269977 | ||
| 2019-01-07 | 8-K | 8K | 1.01,9.01 | 0001096906-19-000008 | 001-12575 | 19512977 | 34 | 21977 | ||
| 2018-12-17 | 4 | PRIMARY DOCUMENT | 0001733614-18-000017 | 4484 | ||||||
| 2018-11-28 | 4 | PRIMARY DOCUMENT | 0001733614-18-000016 | 5492 | ||||||
| 2018-11-16 | 8-K | 8K | 4.01,9.01 | 0001096906-18-000651 | 001-12575 | 181189483 | 34 | 96329 | ||
| 2018-11-07 | 10-Q | 10Q | 0001096906-18-000623 | 001-12575 | 181165347 | 34 | 1458123 | 1 | ||
| 2018-10-30 | 8-K | 8K | 8.01,9.01 | 0001096906-18-000597 | 001-12575 | 181146331 | 34 | 24384 | ||
| 2018-10-23 | 8-K | 8K | 2.02,9.01 | 0001096906-18-000572 | 001-12575 | 181133977 | 34 | 274762 | ||
| 2018-10-18 | 8-K | 8K | 2.02,9.01 | 0001096906-18-000566 | 001-12575 | 181127896 | 34 | 201285 | ||
| 2018-08-09 | 10-Q | 10Q | 0001096906-18-000445 | 001-12575 | 181004531 | 34 | 1409627 | 1 | ||
| 2018-07-30 | 4 | PRIMARY DOCUMENT | 0001733614-18-000015 | 4024 | ||||||
| 2018-06-19 | 4 | PRIMARY DOCUMENT | 0001733614-18-000014 | 4419 | ||||||
| 2018-06-15 | 4 | PRIMARY DOCUMENT | 0001733614-18-000013 | 6008 | ||||||
| 2018-06-13 | 4 | PRIMARY DOCUMENT | 0001733614-18-000012 | 6008 | ||||||
| 2018-06-07 | 4 | PRIMARY DOCUMENT | 0001733614-18-000011 | 4416 | ||||||
| 2018-06-04 | 4 | PRIMARY DOCUMENT | 0001733614-18-000010 | 6003 | ||||||
| 2018-05-31 | SD | FORM SD | 0001096906-18-000283 | 001-12575 | 18870496 | 34 | 15337 | |||
| 2018-05-22 | 4 | PRIMARY DOCUMENT | 0001733614-18-000009 | 4301 | ||||||
| 2018-05-15 | 4 | PRIMARY DOCUMENT | 0001733614-18-000008 | 4293 | ||||||
| 2018-05-10 | 4 | PRIMARY DOCUMENT | 0001733614-18-000007 | 6104 | ||||||
| 2018-05-09 | 10-Q | 10Q | 0001096906-18-000230 | 001-12575 | 18817595 | 34 | 1292438 | 1 | ||
| 2018-05-09 | 4 | PRIMARY DOCUMENT | 0001733614-18-000006 | 4141 | ||||||
| 2018-05-08 | 8-K | 8K | 5.07 | 0001096906-18-000224 | 001-12575 | 18813898 | 34 | 22664 | ||
| 2018-05-07 | 4 | PRIMARY DOCUMENT | 0001733614-18-000005 | 5887 | ||||||
| 2018-04-26 | 8-K | 8K | 2.02,9.01 | 0001096906-18-000212 | 001-12575 | 18776977 | 34 | 253887 | ||
| 2018-04-09 | PX14A6G | PX14A6G | 0001140361-18-017766 | 001-12575 | 18745038 | 34 | 30257 | |||
| 2018-04-03 | 3 | PRIMARY DOCUMENT | 0001733614-18-000004 | 5714 | ||||||
| 2018-04-02 | 8-K | 8K | 5.02 | 0001096906-18-000173 | 001-12575 | 18727864 | 34 | 12514 | ||
| 2018-03-21 | 4 | PRIMARY DOCUMENT | 0001733614-18-000003 | 10146 | ||||||
| 2018-03-14 | 4 | PRIMARY DOCUMENT | 0001733614-18-000002 | 4419 | ||||||
| 2018-03-09 | 4 | PRIMARY DOCUMENT | 0001733614-18-000001 | 6006 | ||||||
| 2018-03-08 | DEF 14A | DEF14A | 0001096906-18-000129 | 001-12575 | 18675746 | 34 | 897083 | |||
| 2018-03-06 | 10-K | 10K | 0001096906-18-000127 | 001-12575 | 18669718 | 34 | 4838597 | 1 | ||
| 2018-02-26 | 4 | PRIMARY DOCUMENT | 0001194248-18-000006 | 4419 | ||||||
| 2018-02-20 | 4 | PRIMARY DOCUMENT | 0001194248-18-000005 | 4026 | ||||||
| 2018-02-20 | 4 | PRIMARY DOCUMENT | 0001194248-18-000004 | 4418 | ||||||
| 2018-02-15 | 4 | PRIMARY DOCUMENT | 0001194248-18-000003 | 4298 | ||||||
| 2018-02-14 | SC 13G/A | utmd13gadec17.txt | 0000080255-18-002287 | 005-34115 | 34 | 9286 | ||||
| 2018-02-14 | SC 13G | utmd-13g_20171231.txt | 0001037389-18-000064 | 005-34115 | 18606651 | 34 | 13089 | |||
| 2018-02-13 | 4 | PRIMARY DOCUMENT | 0001194248-18-000002 | 5882 | ||||||
| 2018-02-13 | SC 13G/A | filing.txt | 0000315066-18-001619 | 005-34115 | 18600156 | 34 | 9325 | |||
| 2018-02-06 | 4 | PRIMARY DOCUMENT | 0001194248-18-000001 | 4292 | ||||||
| 2018-01-30 | 8-K | 8K | 2.02,9.01 | 0001096906-18-000047 | 001-12575 | 18559229 | 34 | 222810 | ||
| 2017-12-15 | 4 | PRIMARY DOCUMENT | 0001194248-17-000004 | 4550 | ||||||
| 2017-11-07 | 10-Q | 10Q | 0001096906-17-000710 | 001-12575 | 171183087 | 34 | 1261799 | 1 | ||
| 2017-10-31 | 8-K | 8K | 8.01,9.01 | 0001096906-17-000699 | 001-12575 | 171165047 | 34 | 17323 | ||
| 2017-10-24 | 8-K | 8K | 2.02,9.01 | 0001096906-17-000687 | 001-12575 | 171150897 | 34 | 156085 | ||
| 2017-08-03 | 10-Q | 10Q | 0001096906-17-000496 | 001-12575 | 171004078 | 34 | 1253400 | 1 | ||
| 2017-07-25 | 8-K | 8K | 2.02,9.01 | 0001096906-17-000478 | 001-12575 | 17980198 | 34 | 171167 | 1 | 1 |
| 2017-05-31 | SD | SD | 0001096906-17-000401 | 001-12575 | 17880887 | 34 | 15370 | |||
| 2017-05-08 | 8-K | FORM 8-K | 5.07 | 0001096906-17-000309 | 001-12575 | 17823311 | 34 | 14737 | ||
| 2017-05-05 | 10-Q | 10Q | 0001096906-17-000302 | 001-12575 | 17819599 | 34 | 1164954 | 1 | ||
| 2017-04-25 | 8-K | 8K | 2.02,9.01 | 0001096906-17-000269 | 001-12575 | 17781521 | 34 | 128567 | ||
| 2017-04-13 | 4 | PRIMARY DOCUMENT | 0001194248-17-000003 | 4550 | ||||||
| 2017-03-10 | DEF 14A | UTAH MEDICAL PROXY | 0001096906-17-000157 | 001-12575 | 17680760 | 34 | 845354 | |||
| 2017-03-08 | 10-K | 10K | 0001096906-17-000145 | 001-12575 | 17674593 | 34 | 4731136 | 1 | ||
| 2017-03-02 | SC 13G/A | utmd13ga3.txt | 0001603715-17-000015 | 005-34115 | 17659241 | 34 | 10032 | |||
| 2017-02-14 | SC 13G/A | filing.txt | 0000315066-17-002119 | 005-34115 | 17605586 | 34 | 9387 | |||
| 2017-02-10 | SC 13G/A | SC 13G/A | 0000052388-17-000020 | 005-34115 | 17591213 | 34 | 137629 | |||
| 2017-02-07 | SC 13G/A | utmd13gadec16.txt | 0000080255-17-001230 | 005-34115 | 34 | 9485 | ||||
| 2017-02-06 | 4 | PRIMARY DOCUMENT | 0001194248-17-000002 | 6464 | ||||||
| 2017-01-31 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8-K | 2.02 | 0001096906-17-000056 | 001-12575 | 17560426 | 34 | 135006 | ||
| 2017-01-03 | 4 | PRIMARY DOCUMENT | 0001194248-17-000001 | 6467 | ||||||
| 2016-12-12 | 4 | PRIMARY DOCUMENT | 0001194248-16-000021 | 6008 | ||||||
| 2016-12-08 | 4 | PRIMARY DOCUMENT | 0001194248-16-000020 | 6007 | ||||||
| 2016-11-30 | 4 | PRIMARY DOCUMENT | 0001194248-16-000019 | 7600 | ||||||
| 2016-11-22 | 4 | PRIMARY DOCUMENT | 0001194248-16-000018 | 5878 | ||||||
| 2016-11-17 | 4 | PRIMARY DOCUMENT | 0001194248-16-000017 | 5884 | ||||||
| 2016-11-16 | 4 | PRIMARY DOCUMENT | 0001194248-16-000016 | 4554 | ||||||
| 2016-11-04 | 10-Q | 10Q | 0001096906-16-002007 | 001-12575 | 161974864 | 34 | 1298841 | 1 | ||
| 2016-11-01 | 8-K | FORM 8-K | 8.01,9.01 | 0001096906-16-001979 | 001-12575 | 161963904 | 34 | 14723 | ||
| 2016-10-26 | 8-K | 8K | 2.02,9.01 | 0001096906-16-001964 | 001-12575 | 161951241 | 34 | 171465 | ||
| 2016-09-15 | 4 | PRIMARY DOCUMENT | 0001194248-16-000015 | 4420 | ||||||
| 2016-09-12 | 4 | PRIMARY DOCUMENT | 0001194248-16-000014 | 4298 | ||||||
| 2016-09-08 | 4 | PRIMARY DOCUMENT | 0001194248-16-000013 | 4300 | ||||||
| 2016-09-08 | 4 | PRIMARY DOCUMENT | 0001194248-16-000012 | 6007 | ||||||
| 2016-08-31 | 4 | PRIMARY DOCUMENT | 0001194248-16-000011 | 6010 | ||||||
| 2016-08-16 | 4 | PRIMARY DOCUMENT | 0001194248-16-000010 | 4414 | ||||||
| 2016-08-12 | 4 | PRIMARY DOCUMENT | 0001194248-16-000009 | 4486 | ||||||
| 2016-08-08 | 10-Q | UTAH MEDICAL PRODUCTS, INC. 10Q 2016-06-29 | 0001096906-16-001810 | 001-12575 | 161815274 | 34 | 1274854 | 1 | ||
| 2016-07-26 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 | 2.02,9.01 | 0001096906-16-001767 | 001-12575 | 161784085 | 34 | 150679 | ||
| 2016-07-26 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 | 2.02,9.01 | 0001096906-16-001766 | 001-12575 | 161784081 | 34 | 150679 | ||
| 2016-07-26 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2016-07-26 | 2.02,9.01 | 0001096906-16-001765 | 001-12575 | 161784078 | 34 | 150679 | ||
| 2016-06-01 | 4 | PRIMARY DOCUMENT | 0001194248-16-000008 | 4921 | ||||||
| 2016-05-31 | SD | FORM SD | 0001096906-16-001658 | 001-12575 | 161684783 | 34 | 13441 | |||
| 2016-05-27 | 4 | PRIMARY DOCUMENT | 0001194248-16-000007 | 6153 | ||||||
| 2016-05-19 | 4 | PRIMARY DOCUMENT | 0001194248-16-000006 | 6467 | ||||||
| 2016-05-06 | 10-Q | UTAH MEDICAL PRODUCTS, INC. 10Q 2016-03-31 | 0001096906-16-001582 | 001-12575 | 161627049 | 34 | 1190016 | 1 | ||
| 2016-05-02 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2016-04-29 | 5.07 | 0001096906-16-001571 | 001-12575 | 161612088 | 34 | 16906 | ||
| 2016-04-26 | 8-K | FORM 8-K | 2.02,9.01 | 0001096906-16-001560 | 001-12575 | 161592011 | 34 | 115149 | 1 | |
| 2016-04-01 | 4 | PRIMARY DOCUMENT | 0001194248-16-000005 | 4577 | ||||||
| 2016-03-10 | 10-K | UTAH MEDICAL PRODUCTS, INC. 10K 2015-12-31 | 0001096906-16-001451 | 001-12575 | 161496792 | 34 | 4676980 | 1 | ||
| 2016-03-10 | DEF 14A | UTAH MEDICAL PROXY | 0001096906-16-001449 | 001-12575 | 161496778 | 34 | 793115 | |||
| 2016-02-16 | SC 13G/A | NINE TEN CAPITAL PARTNERS LP SC 13GA NO2 12-31-2015 (UTAH MEDICAL PRODUCTS INC) | 0001140361-16-053326 | 005-34115 | 161429490 | 34 | 130483 | |||
| 2016-02-12 | SC 13G/A | filing.txt | 0000315066-16-005550 | 005-34115 | 161415331 | 34 | 9260 | |||
| 2016-02-11 | SC 13G/A | SCHEDULE 13G/A | 0000052388-16-000133 | 005-34115 | 161411068 | 34 | 179963 | |||
| 2016-02-10 | SC 13G/A | UTMD AS OF 12/31/2015 | 0000080255-16-000907 | 005-34115 | 161405319 | 34 | 34179 | |||
| 2016-02-02 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2016-02-02 | 2.02 | 0001096906-16-001349 | 001-12575 | 161380193 | 34 | 140258 | ||
| 2015-12-16 | CORRESP | filename1.htm | 0001096906-15-001282 | 96008 | ||||||
| 2015-12-03 | UPLOAD | filename1.pdf | 0000000000-15-056403 | 159140 | ||||||
| 2015-11-06 | 10-Q | UTAH MEDICAL PRODUCTS, INC. 10Q 2015-09-30 | 0001096906-15-001137 | 001-12575 | 151207097 | 34 | 1443790 | 1 | ||
| 2015-11-03 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2015-11-03 | 8.01,9.01 | 0001096906-15-001123 | 001-12575 | 151192987 | 34 | 19004 | ||
| 2015-10-29 | 4 | PRIMARY DOCUMENT | 0001194248-15-000004 | 4577 | ||||||
| 2015-10-22 | 8-K | FORM 8-K | 2.02,9.01 | 0001096906-15-001084 | 001-12575 | 151169792 | 34 | 188270 | ||
| 2015-08-07 | 10-Q | UTAH MEDICAL PRODUCTS, INC.10Q 2015-06-30 | 0001096906-15-000860 | 001-12575 | 151038063 | 34 | 1512211 | 1 | ||
| 2015-07-23 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2015-07-23 | 2.02,9.01 | 0001096906-15-000800 | 001-12575 | 151002319 | 34 | 199114 | ||
| 2015-06-01 | SD | FORM SD | 0001096906-15-000614 | 001-12575 | 15902576 | 34 | 19512 | |||
| 2015-05-13 | 4 | PRIMARY DOCUMENT | 0001194248-15-000003 | 7933 | ||||||
| 2015-05-06 | 10-Q | UTAH MEDICAL PRODUCTS, INC. 10-Q 2015-03-31 | 0001096906-15-000483 | 001-12575 | 15837325 | 34 | 1670932 | 1 | ||
| 2015-05-04 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2015-05-01 | 5.07 | 0001096906-15-000461 | 001-12575 | 15828795 | 34 | 25873 | ||
| 2015-04-23 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2015-04-23 | 2.02,9.01 | 0001096906-15-000421 | 001-12575 | 15788684 | 34 | 143832 | ||
| 2015-04-21 | 4 | PRIMARY DOCUMENT | 0001194248-15-000002 | 6466 | ||||||
| 2015-04-09 | 4 | PRIMARY DOCUMENT | 0001194248-15-000001 | 4576 | ||||||
| 2015-03-12 | DEF 14A | UTAH MEDICAL PRODUCTS, INC. DEF 14A 2015-03-10 | 0001096906-15-000242 | 001-12575 | 15695707 | 34 | 713822 | |||
| 2015-03-12 | 10-K | UTAH MEDICAL PRODUCTS, INC. 10K 2014-12-31 | 0001096906-15-000240 | 001-12575 | 15695696 | 34 | 6639521 | 1 | ||
| 2015-02-17 | SC 13G/A | NINE TEN PARTNERS LP SC 13GA NO1 12-31-2014 (UTAH MEDICAL) | 0001140361-15-007296 | 005-34115 | 15622267 | 34 | 147521 | |||
| 2015-02-10 | SC 13G/A | UTMD AS OF 12/31/2014 | 0000080255-15-000080 | 005-34115 | 15592866 | 34 | 34165 | |||
| 2015-02-10 | SC 13G/A | SCHEDULE 13G/A | 0000052388-15-000036 | 005-34115 | 15591936 | 34 | 176182 | |||
| 2015-01-29 | 8-K | FORM 8-K | 2.02 | 0001096906-15-000107 | 001-12575 | 15558038 | 34 | 154819 | ||
| 2014-11-12 | 4 | PRIMARY DOCUMENT | 0001194248-14-000010 | 6006 | ||||||
| 2014-11-04 | 10-Q | UTAH MEDICAL PRODUCTS, INC. 10Q 2014-09-30 | 0001096906-14-001487 | 001-12575 | 141192838 | 34 | 1751292 | 1 | ||
| 2014-11-04 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2014-11-04 | 8.01,9.01 | 0001096906-14-001484 | 001-12575 | 141192749 | 34 | 20987 | ||
| 2014-11-04 | 8-K | UTAH MEDICAL PRODUCTS, INC. 8K 2014-10-31 | 1.01 | 0001096906-14-001481 | 001-12575 | 141192054 | 34 | 117125 | ||
| 2014-10-27 | 4 | PRIMARY DOCUMENT | 0001194248-14-000009 | 4577 | ||||||
| 2014-10-24 | 8-K | FORM 8-K | 1.01 | 0001096906-14-001444 | 001-12575 | 141171625 | 34 | 26122 | ||
| 2014-10-23 | 8-K | FORM 8-K | 2.02 | 0001096906-14-001439 | 001-12575 | 141169322 | 34 | 162662 | ||
| 2014-10-15 | S-8 | FORM S-8 | 0001096906-14-001419 | 333-199337 | 141157569 | 33 | 145152 | |||
| 2014-10-10 | 4 | PRIMARY DOCUMENT | 0001194248-14-000008 | 6468 | ||||||
| 2014-08-08 | 10-Q | UTAH MEDICAL PRODUCTS, INC. 10Q 2014-06-30 | 0001096906-14-001021 | 001-12575 | 141027020 | 34 | 1751282 | 1 | ||
| 2014-07-24 | 8-K | FORM 8-K | 2.02 | 0001096906-14-000941 | 001-12575 | 14990523 | 34 | 165193 | ||
| 2014-07-10 | SC 13G | NTCM 13G | 0001603715-14-000008 | 005-34115 | 14969440 | 34 | 6654 | |||
| 2014-07-10 | SC 13G/A | BCM 13G-A9 | 0001340807-14-000031 | 005-34115 | 14969301 | 34 | 6457 | |||
| 2014-06-10 | SC 13G/A | UTMD 13GA-8 | 0001340807-14-000023 | 005-34115 | 14901592 | 34 | 6319 | |||
| 2014-06-02 | SD | UTAH MEDICAL PRODUCTS INC SD 12-31-2013 | 0001140361-14-024066 | 001-12575 | 14884080 | 34 | 16583 | |||
| 2014-05-07 | 4 | PRIMARY DOCUMENT | 0001194248-14-000007 | 5254 | ||||||
| 2014-05-07 | 10-Q | UTAH MEDICAL PRODUCTS, INC. 10-Q 2014-03-31 | 0001096906-14-000606 | 001-12575 | 14820471 | 34 | 1627099 | 1 | ||
| 2014-05-06 | 4 | PRIMARY DOCUMENT | 0001194248-14-000006 | 7931 | ||||||
| 2014-05-06 | 8-K | UTAH MEDICAL PRODUCTS, INC. FORM 8-K | 5.07 | 0001096906-14-000593 | 001-12575 | 14816349 | 34 | 20554 | ||
| 2014-04-24 | 8-K | UTAH MEDICAL PRODUCTS, INC. FORM 8-K | 2.02 | 0001096906-14-000529 | 001-12575 | 14781045 | 34 | 126031 | ||
| 2014-04-01 | 4 | PRIMARY DOCUMENT | 0001194248-14-000005 | 6156 | ||||||
| 2014-03-14 | 4 | PRIMARY DOCUMENT | 0001194248-14-000004 | 5883 | ||||||
| 2014-03-12 | DEF 14A | UTAH MEDICAL PRODUCTS, INC. DEF 14A | 0001096906-14-000295 | 001-12575 | 14687354 | 34 | 788275 | |||
| 2014-03-12 | 10-K | UTAH MEDICAL PRODUCTS, INC. 10-K 2013-12-31 | 0001096906-14-000293 | 001-12575 | 14687343 | 34 | 6779393 | 1 | ||
| 2014-03-10 | 4 | PRIMARY DOCUMENT | 0001194248-14-000003 | 6006 | ||||||
| 2014-03-06 | 4 | PRIMARY DOCUMENT | 0001194248-14-000002 | 6007 | ||||||
| 2014-02-28 | 4 | PRIMARY DOCUMENT | 0001194248-14-000001 | 6007 | ||||||
| 2014-02-18 | SC 13G/A | UTMD 13G-A7 | 0001340807-14-000013 | 005-34115 | 14620387 | 34 | 6320 | |||
| 2014-02-14 | SC 13G/A | filing.txt | 0000315066-14-002604 | 005-34115 | 14610282 | 34 | 8043 | |||
| 2014-02-13 | SC 13G/A | SCHEDULE 13G/A | 0000052388-14-000052 | 005-34115 | 14605254 | 34 | 142685 | |||
| 2014-02-13 | 8-K | FORM 8-K | 5.03 | 0001096906-14-000174 | 001-12575 | 14603341 | 34 | 276817 | ||
| 2014-02-10 | SC 13G/A | UTMD AS OF 12/31/2013 | 0000080255-14-000171 | 005-34115 | 14588063 | 34 | 38083 | |||
| 2014-01-30 | 8-K | UTAH MEDICAL PRODUCTS, INC FORM 8-K | 2.02 | 0001096906-14-000092 | 001-12575 | 14559500 | 34 | 146513 | ||
| 2013-12-11 | CORRESP | filename1.htm | 0001096906-13-001854 | 33293 | ||||||
| 2013-12-10 | 4 | PRIMARY DOCUMENT | 0001194248-13-000018 | 6008 | ||||||
| 2013-12-05 | 4 | PRIMARY DOCUMENT | 0001194248-13-000017 | 6010 | ||||||
| 2013-11-27 | UPLOAD | filename1.pdf | 0000000000-13-065087 | 156014 | ||||||
| 2013-11-26 | 4 | PRIMARY DOCUMENT | 0001194248-13-000016 | 8315 | ||||||
| 2013-11-22 | 4 | PRIMARY DOCUMENT | 0001194248-13-000015 | 6006 | ||||||
| 2013-11-15 | 4 | PRIMARY DOCUMENT | 0001194248-13-000014 | 6007 | ||||||
| 2013-11-12 | CORRESP | filename1.htm | 0001096906-13-001677 | 62301 | ||||||
| 2013-11-06 | 10-Q | UTAH MEDICAL PRODUCTS, INC. 10Q 2013-09-30 | 0001096906-13-001652 | 001-12575 | 131196594 | 34 | 1697899 | 1 | ||
| 2013-10-31 | 4 | PRIMARY DOCUMENT | 0001194248-13-000013 | 6007 | ||||||
| 2013-10-29 | 8-K | FORM 8-K | 8.01 | 0001096906-13-001600 | 001-12575 | 131175554 | 34 | 19366 | ||
| 2013-10-24 | 8-K | FORM 8-K | 2.02 | 0001096906-13-001597 | 001-12575 | 131167693 | 34 | 152323 | ||
| 2013-10-11 | UPLOAD | filename1.pdf | 0000000000-13-056388 | 162222 | ||||||
| 2013-10-01 | CORRESP | filename1.htm | 0001096906-13-001542 | 26747 | ||||||
| 2013-09-19 | UPLOAD | filename1.pdf | 0000000000-13-051710 | 158974 | ||||||
| 2013-09-13 | CORRESP | filename1.htm | 0001096906-13-001481 | 40448 | ||||||
| 2013-09-12 | 4 | PRIMARY DOCUMENT | 0001194248-13-000012 | 7595 | ||||||
| 2013-09-03 | 4 | PRIMARY DOCUMENT | 0001194248-13-000011 | 5886 | ||||||
| 2013-08-30 | UPLOAD | filename1.pdf | 0000000000-13-047997 | 162892 | ||||||
| 2013-08-26 | 4 | PRIMARY DOCUMENT | 0001194248-13-000010 | 6047 | ||||||
| 2013-08-15 | 4 | PRIMARY DOCUMENT | 0001194248-13-000009 | 4460 | ||||||
| 2013-08-12 | 4 | PRIMARY DOCUMENT | 0001194248-13-000008 | 6044 | ||||||
| 2013-08-08 | 10-Q | UTAH MEDICAL PRODUCTS, INC., 10Q 2013-06-30 | 0001096906-13-001234 | 001-12575 | 131021060 | 34 | 2235405 | 1 | ||
| 2013-08-07 | 4 | PRIMARY DOCUMENT | 0001194248-13-000007 | 6047 |
One latest value per concept from companyfacts (319 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 2.85M | 2026-11-12 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| dei | EntityListingParValuePerShare | Entity Listing, Par Value Per Share | USD/shares | 0.01 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 |
| dei | EntityPublicFloat | Entity Public Float | USD | 168.20M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 0 | 2026-09-29 | SC TO-I/A | 2026-09-29 | 0001096906-26-001481 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 6,732.38 | 2026-09-29 | SC TO-I/A | 2026-09-29 | 0001096906-26-001481 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-09-29 | SC TO-I/A | 2026-09-29 | 0001096906-26-001481 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 6,732.38 | 2026-09-29 | SC TO-I/A | 2026-09-29 | 0001096906-26-001481 | |||
| ffd | TtlTxValtn | TtlTxValtn | USD | 48.75M | 2026-09-29 | SC TO-I/A | 2026-09-29 | 0001096906-26-001481 | |||
| us-gaap | AcceleratedShareRepurchasesFinalPricePaidPerShare | Accelerated Share Repurchases, Final Price Paid Per Share | USD/shares | 64.7 | 2024-10-01 | 2024-11-11 | 2024 | Q3 | 10-Q | 2024-11-12 | 0001811884-24-000022 |
| us-gaap | AccountsAndOtherReceivablesNetCurrent | Accounts and Other Receivables, Net, Current | USD | 3.52M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 1.68M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | AccountsReceivableGrossCurrent | Accounts Receivable, before Allowance for Credit Loss, Current | USD | 4.04M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 3.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | AccruedIncomeTaxesCurrent | Accrued Income Taxes, Current | USD | 327,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 3.06M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 25.34M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossBeforeTax | Accumulated Other Comprehensive Income (Loss), before Tax (Deprecated 2009-01-31) | USD | -3.37M | 2013-03-31 | 2013 | Q1 | 10-Q | 2013-05-08 | 0001096906-13-000677 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossBeforeTax1 | AOCI Including Portion Attributable to Noncontrolling Interest, before Tax | USD | -10.02M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | AdjustmentForAmortization | Amortization | USD | 5.00M | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-12 | 0001811884-21-000016 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation | USD | 50,000 | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 |
| us-gaap | AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities | Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities | USD | -85,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 373,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | AllowanceForDoubtfulAccountsReceivableCurrent | Accounts Receivable, Allowance for Credit Loss, Current | USD | 515,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | AmortizationOfIntangibleAssets | Amortization of Intangible Assets | USD | 514,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | Assets | Assets | USD | 128.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 100.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | AvailableForSaleSecurities | Available-for-sale Securities | USD | -183,000 | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-09 | 0001096906-12-002669 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 | |
| us-gaap | AvailableForSaleSecuritiesAmortizedCost | Available-for-sale Securities, Amortized Cost Basis | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 | |
| us-gaap | AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2 | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) | USD | 9,000 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-12 | 0001096906-15-000240 | |
| us-gaap | AvailableForSaleSecuritiesEquitySecurities | Available-for-sale Securities, Equity Securities | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 | |
| us-gaap | AvailableForSaleSecuritiesGrossRealizedGains | Available-for-sale Securities, Gross Realized Gains | USD | 32,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 |
| us-gaap | AvailableForSaleSecuritiesGrossRealizedLosses | Available-for-sale Securities, Gross Realized Losses | USD | 12,000 | 2012-01-01 | 2012-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 |
| us-gaap | AvailableforsaleSecuritiesGrossUnrealizedGain | Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) | USD | 16,000 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-12 | 0001096906-15-000240 | |
| us-gaap | AvailableForSaleSecuritiesGrossUnrealizedGainLoss | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2013-01-31) | USD | 2,000 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-12 | 0001096906-15-000240 | |
| us-gaap | AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) | USD | -6,000 | 2015-07-01 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-06 | 0001096906-15-001137 |
| us-gaap | AvailableForSaleSecuritiesGrossUnrealizedLosses1 | Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) | USD | -316,000 | 2011-12-31 | 2012 | FY | 10-K | 2013-03-07 | 0001096906-13-000305 | |
| us-gaap | AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss | Available-for-sale Securities, Income Tax Expense on Change in Unrealized Holding Gain (Loss) (Deprecated 2018-01-31) | USD | 3,000 | 2015-07-01 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-06 | 0001096906-15-001137 |
| us-gaap | BuildingsAndImprovementsGross | Buildings and Improvements, Gross | USD | 14.38M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationAssetsAcquired | Business Acquisition, Purchase Price Allocation, Assets Acquired (Deprecated 2013-01-31) | USD | 51.92M | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet | Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net (Deprecated 2013-01-31) | USD | 41.08M | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationCurrentAssetsInventory | Business Acquisition, Purchase Price Allocation, Current Assets, Inventory (Deprecated 2013-01-31) | USD | 1.32M | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationCurrentAssetsPrepaidExpenseAndOtherAssets | Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets (Deprecated 2013-01-31) | USD | 773,000 | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationCurrentAssetsReceivables | Business Acquisition, Purchase Price Allocation, Current Assets, Receivables (Deprecated 2013-01-31) | USD | 2.18M | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesAccountsPayable | Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable (Deprecated 2013-01-31) | USD | 1.11M | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesAccruedLiabilities | Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities (Deprecated 2013-01-31) | USD | 644,000 | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationDeferredTaxLiabilitiesNoncurrent | Business Acquisition, Purchase Price Allocation, Deferred Tax Liabilities, Noncurrent (Deprecated 2013-01-31) | USD | 9.08M | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationGoodwillAmount | Business Acquisition, Purchase Price Allocation, Goodwill Amount (Deprecated 2013-01-31) | USD | 8.25M | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationLiabilitiesAssumed | Business Acquisition, Purchase Price Allocation, Liabilities Assumed (Deprecated 2013-01-31) | USD | 10.84M | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationPropertyPlantAndEquipment | Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment (Deprecated 2013-01-31) | USD | 606,000 | 2011-03-18 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | BusinessAcquisitionsProFormaNetIncomeLoss | Business Acquisition, Pro Forma Net Income (Loss) | USD | 10.17M | 2012-01-01 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-07 | 0001096906-13-000305 |
| us-gaap | BusinessAcquisitionsProFormaRevenue | Business Acquisition, Pro Forma Revenue | USD | 41.55M | 2012-01-01 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-07 | 0001096906-13-000305 |
| us-gaap | BusinessCombinationAcquiredReceivablesGrossContractualAmount | Business Combination, Acquired Receivables, Gross Contractual Amount | USD | 681,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationAcquisitionRelatedCosts | Business Combination, Acquisition Related Costs | USD | 173 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets | USD | 6.16M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation | Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation | USD | 26,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | USD | 506,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other | USD | 15,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets | USD | 21,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | USD | 305,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other | USD | 26,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory | USD | 857,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | USD | 1.26M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | USD | 4.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | USD | 381,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 85.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | -3.17M | 2020-01-01 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001445866-20-000588 |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 85.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -554,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | CommitmentsAndContingencies | Commitments and Contingencies | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 50.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 3.17M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 3.17M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 32,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | 7.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | ConstructionInProgressGross | Construction in Progress, Gross | USD | 110,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | ContractualObligation | Contractual Obligation | USD | 4.34M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | CostOfGoodsAndServicesSold | Cost of Goods and Services Sold | USD | 10.99M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | CostOfGoodsSold | Cost of Goods Sold (Deprecated 2018-01-31) | USD | 7.95M | 2018-01-01 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-09 | 0001096906-18-000445 |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | 2.65M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | CurrentForeignTaxExpenseBenefit | Current Foreign Tax Expense (Benefit) | USD | 319,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | 3.44M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 474,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | DeferredFederalIncomeTaxExpenseBenefit | Deferred Federal Income Tax Expense (Benefit) | USD | -44,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | DeferredForeignIncomeTaxExpenseBenefit | Deferred Foreign Income Tax Expense (Benefit) | USD | -559,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | DeferredIncomeTaxesAndOtherAssetsCurrent | Deferred Income Taxes and Other Assets, Current | USD | 393,000 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-08 | 0001096906-17-000145 | |
| us-gaap | DeferredIncomeTaxesAndOtherAssetsNoncurrent | Deferred Income Taxes and Other Assets, Noncurrent | USD | 777,000 | 2011-09-30 | 2011 | Q3 | 10-Q | 2011-11-07 | 0001096906-11-002591 | |
| us-gaap | DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent | Deferred Income Taxes and Other Tax Liabilities, Noncurrent | USD | 944,000 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | -148,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | DeferredIncomeTaxLiabilitiesNet | Deferred Income Tax Liabilities, Net | USD | 303,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | DeferredStateAndLocalIncomeTaxExpenseBenefit | Deferred State and Local Income Tax Expense (Benefit) | USD | -10,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | DeferredTaxAssetsInventory | Deferred Tax Assets, Inventory | USD | 254,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | -3.56M | 2017-12-31 | 2017 | FY | 10-K | 2018-03-06 | 0001096906-18-000127 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001096906-20-000111 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | USD | 43,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts | USD | 76,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | DeferredTaxExpenseFromStockOptionsExercised | Deferred Tax Expense from Stock Options Exercised | USD | 0 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-12 | 0001096906-26-001210 |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 488,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | DeferredTaxLiabilitiesGoodwillAndIntangibleAssets | Deferred Tax Liabilities, Goodwill and Intangible Assets | USD | 8.05M | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-09 | 0001096906-12-002669 | |
| us-gaap | DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets | Deferred Tax Liabilities, Intangible Assets | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | DeferredTaxLiabilitiesNoncurrent | Deferred Tax Liabilities, Net, Noncurrent | USD | 521,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001096906-20-000111 | |
| us-gaap | DefinedContributionPlanEmployerDiscretionaryContributionAmount | Defined Contribution Plan, Employer Discretionary Contribution Amount | USD | 211,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | Depreciation | Depreciation | USD | 638,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | DepreciationAndAmortization | Depreciation, Depletion and Amortization, Nonproduction | USD | 820,000 | 2012-01-01 | 2012-03-31 | 2012 | Q1 | 10-Q | 2012-05-09 | 0001096906-12-001242 |
| us-gaap | DividendsCommonStockCash | Dividends, Common Stock, Cash | USD | 2.96M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | DueFromOtherRelatedPartiesCurrent | Due from Other Related Parties, Current | USD | 15,000 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-07 | 0001096906-13-000305 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | 2.54 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | 2.54 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0.239 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | 0.003 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | -0.004 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.036 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | 0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsAmount | Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Amount | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K/A | 2023-03-28 | 0001811884-23-000008 |
| us-gaap | EffectOfExchangeRateOnCashAndCashEquivalents | Effect of Exchange Rate on Cash and Cash Equivalents | USD | -362,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-25 | 0001811884-22-000004 |
| us-gaap | EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | -243,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 853,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 1.01M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions | Share-based Payment Arrangement, Exercise of Option, Tax Benefit | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions | Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options (Deprecated 2017-01-31) | USD | 50,000 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-08 | 0001096906-17-000145 |
| us-gaap | ExcessTaxBenefitFromShareBasedCompensationOperatingActivities | Excess Tax Benefit from Share-based Compensation, Operating Activities | USD | -39,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-25 | 0001811884-22-000004 |
| us-gaap | FairValueMeasuredOnRecurringBasisInvestments | Fair Value, Measured on Recurring Basis, Investments (Deprecated 2011-01-31) | USD | 47,000 | 2013-03-31 | 2013 | Q1 | 10-Q | 2013-05-08 | 0001096906-13-000677 | |
| us-gaap | FiniteLivedCustomerRelationshipsGross | Finite-Lived Customer Relationships, Gross | USD | 9.61M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedIntangibleAssetsAccumulatedAmortization | Finite-Lived Intangible Assets, Accumulated Amortization | USD | 34.16M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths | Finite-Lived Intangible Asset, Expected Amortization, Year One | USD | 433,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive | Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five | USD | 1.98M | 2016-12-31 | 2016 | FY | 10-K | 2017-03-08 | 0001096906-17-000145 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour | Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four | USD | 1.98M | 2016-12-31 | 2016 | FY | 10-K | 2017-03-08 | 0001096906-17-000145 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFive | Finite-Lived Intangible Asset, Expected Amortization, Year Five | USD | 9,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFour | Finite-Lived Intangible Asset, Expected Amortization, Year Four | USD | 9,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearThree | Finite-Lived Intangible Asset, Expected Amortization, Year Three | USD | 10,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo | Finite-Lived Intangible Asset, Expected Amortization, Year Two | USD | 12,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedIntangibleAssetsFutureAmortizationExpense | Finite-Lived Intangible Assets, Future Amortization Expense (Deprecated 2012-01-31) | USD | 2.60M | 2017-01-01 | 2017-12-31 | 2012 | FY | 10-K | 2013-03-07 | 0001096906-13-000305 |
| us-gaap | FiniteLivedIntangibleAssetsGross | Finite-Lived Intangible Assets, Gross | USD | 38.05M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | FiniteLivedIntangibleAssetsNet | Finite-Lived Intangible Assets, Net | USD | 840,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedNoncompeteAgreementsGross | Finite-Lived Noncompete Agreements, Gross | USD | 134,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedPatentsGross | Finite-Lived Patents, Gross | USD | 2.22M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | FiniteLivedTrademarksGross | Finite-Lived Trademarks, Gross | USD | 9.87M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | ForeignCurrencyExchangeRateTranslation | Foreign Currency Exchange Rate, Translation (Deprecated 2012-01-31) | pure | 1.626 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-07 | 0001096906-13-000305 | |
| us-gaap | ForeignCurrencyExchangeRateTranslation1 | Foreign Currency Exchange Rate, Translation | pure | 1.559 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-12 | 0001096906-15-000240 | |
| us-gaap | GainLossOnDispositionOfAssets | Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K/A | 2023-03-28 | 0001811884-23-000008 |
| us-gaap | GainLossOnInvestments | Gain (Loss) on Investments | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-26 | 0001811884-21-000004 |
| us-gaap | GainLossOnSaleOfInvestments | Gain (Loss) on Sale of Investments | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-26 | 0001811884-21-000004 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 7.88M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | Goodwill | Goodwill | USD | 13.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | GoodwillAcquiredDuringPeriod | Goodwill, Acquired During Period | USD | 0 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 |
| us-gaap | GoodwillForeignCurrencyTranslationGainLoss | Goodwill, Foreign Currency Translation Gain (Loss) | USD | 472,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | GoodwillImpairmentLoss | Goodwill, Impairment Loss | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | GrossProfit | Gross Profit | USD | 14.88M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | 11.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | 9.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | 2.31M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | USD | 8.72M | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-06 | 0001811884-21-000012 |
| us-gaap | IncomeTaxesPaid | Income Taxes Paid | USD | 2.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IncomeTaxesReceivable | Income Taxes Receivable, Current | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 | |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 1.79M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IncomeTaxExpenseBenefitContinuingOperations | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) | USD | 3.07M | 2013-01-01 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 |
| us-gaap | IncomeTaxPaidFederalAfterRefundReceived | IncomeTaxPaidFederalAfterRefundReceived | USD | 2.90M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | IncomeTaxPaidForeignAfterRefundReceived | IncomeTaxPaidForeignAfterRefundReceived | USD | 4.30M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | IncomeTaxReconciliationDeductionsQualifiedProductionActivities | Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Amount | USD | 6,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-25 | 0001811884-22-000004 |
| us-gaap | IncomeTaxReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | USD | -1,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001096906-25-000308 | |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | 2.48M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 30,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | -43,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 428,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 15,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | 778,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | -338,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets | Increase (Decrease) in Accounts Receivable and Other Operating Assets | USD | 60,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 1.41M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IncreaseDecreaseInDeferredIncomeTaxes | Increase (Decrease) in Deferred Income Taxes | USD | -659,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncreaseDecreaseInDeferredRevenue | Increase (Decrease) in Deferred Revenue | USD | 0 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001096906-16-001451 |
| us-gaap | IncreaseDecreaseInInventories | Increase (Decrease) in Inventories | USD | 2.73M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IncreaseDecreaseInOperatingCapital | Increase (Decrease) in Operating Capital | USD | 203,000 | 2014-01-01 | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-08 | 0001096906-14-001021 |
| us-gaap | IncreaseDecreaseInOtherNoncurrentLiabilities | Increase (Decrease) in Other Noncurrent Liabilities | USD | 0 | 2014-01-01 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-04 | 0001096906-14-001487 |
| us-gaap | IncreaseDecreaseInOtherOperatingLiabilities | Increase (Decrease) in Other Operating Liabilities | USD | 0 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001096906-16-001451 |
| us-gaap | IncreaseDecreaseInOtherReceivables | Increase (Decrease) in Other Receivables | USD | 5,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 382,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | IntangibleAssetsNetExcludingGoodwill | Intangible Assets, Net (Excluding Goodwill) | USD | 3.88M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | InterestExpense | Interest Expense | USD | 65,000 | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-06 | 0001096906-18-000127 |
| us-gaap | InterestIncomeSecuritiesTaxExempt | Interest Income, Securities, Operating, Tax Exempt | USD | 201,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001096906-25-000308 | |
| us-gaap | InterestPaid | Interest Paid, Including Capitalized Interest, Operating and Investing Activities | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | InterestReceivableAndOtherAssets | Interest Receivable and Other Assets | USD | 53,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 | |
| us-gaap | InventoryFinishedGoodsNetOfReserves | Inventory, Finished Goods, Net of Reserves | USD | 2.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | InventoryNet | Inventory, Net | USD | 10.57M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | InventoryRawMaterials | Inventory, Raw Materials, Gross | USD | 5.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | InventoryWorkInProcess | Inventory, Work in Process, Gross | USD | 2.03M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | InvestmentsFairValueDisclosure | Investments, Fair Value Disclosure | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 | |
| us-gaap | Land | Land | USD | 1.70M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 307,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 32,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 60,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 47,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 46,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 45,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 56,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 21,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | Liabilities | Liabilities | USD | 5.22M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 128.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 4.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | LitigationReserve | Estimated Litigation Liability | USD | 68,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LitigationReserveCurrent | Estimated Litigation Liability, Current | USD | 68,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LongTermDebt | Long-term Debt | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | LongTermDebtAndCapitalLeaseObligations | Long-term Debt and Lease Obligation | USD | 180,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths | Long-Term Debt, Maturity, Year One | USD | 4,052 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour | Long-Term Debt, Maturity, Year Four | USD | 1,000 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-07 | 0001096906-13-000305 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree | Long-Term Debt, Maturity, Year Three | USD | 1,013 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo | Long-Term Debt, Maturity, Year Two | USD | 4,052 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 | |
| us-gaap | LongTermNotesPayable | Notes Payable, Noncurrent | USD | 0 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001096906-16-001451 | |
| us-gaap | MachineryAndEquipmentGross | Machinery and Equipment, Gross | USD | 19.05M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | -3.76M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -4.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | 7.99M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | NotesPayableCurrent | Notes Payable, Current | USD | 0 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001096906-16-001451 | |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 6.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | 8.01M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 67,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 286,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 60,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 226,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 286,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 45,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 618,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 60,000 | 2020-12-31 | 2021 | Q2 | 10-Q | 2021-08-06 | 0001811884-21-000012 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 45,000 | 2020-12-31 | 2021 | Q2 | 10-Q | 2021-08-06 | 0001811884-21-000012 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 45,000 | 2020-12-31 | 2021 | Q2 | 10-Q | 2021-08-06 | 0001811884-21-000012 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 45,000 | 2020-12-31 | 2021 | Q2 | 10-Q | 2021-08-06 | 0001811884-21-000012 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 45,000 | 2020-12-31 | 2021 | Q2 | 10-Q | 2021-08-06 | 0001811884-21-000012 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueThereafter | Operating Leases, Future Minimum Payments, Due Thereafter | USD | 254,000 | 2020-12-31 | 2021 | Q2 | 10-Q | 2021-08-06 | 0001811884-21-000012 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 59,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.041 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 1.68M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 898,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax (Deprecated 2012-01-31) | USD | -2.52M | 2013-01-01 | 2013-03-31 | 2013 | Q1 | 10-Q | 2013-05-08 | 0001096906-13-000677 |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent | USD | 819,000 | 2012-01-01 | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-09 | 0001096906-12-002669 |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTax | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Deprecated 2012-01-31) | USD | 0 | 2013-01-01 | 2013-03-31 | 2013 | Q1 | 10-Q | 2013-05-08 | 0001096906-13-000677 |
| us-gaap | OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | USD | -602,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001096906-20-000111 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001096906-20-000111 |
| us-gaap | OtherFiniteLivedIntangibleAssetsGross | Other Finite-Lived Intangible Assets, Gross | USD | 21.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | OtherInterestAndDividendIncome | Other Interest and Dividend Income | USD | 2.81M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001096906-25-000308 | |
| us-gaap | OtherLongTermDebtNoncurrent | Other Long-term Debt, Noncurrent | USD | 241,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-14 | 0001096906-25-001839 | |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | 1.86M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | OtherOperatingIncomeExpenseNet | Other Operating Income (Expense), Net | USD | -32,000 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-06 | 0001096906-18-000127 |
| us-gaap | OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities | Other than Temporary Impairment Losses, Investments, Available-for-sale Securities | USD | 290,000 | 2012-01-01 | 2012-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 |
| us-gaap | PaymentsForRepurchaseOfCommonStock | Payments for Repurchase of Common Stock | USD | 905,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | PaymentsOfDividends | Payments of Dividends | USD | 2.96M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | PaymentsToAcquireBusinessesNetOfCashAcquired | Payments to Acquire Businesses, Net of Cash Acquired | USD | 4.04M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | PaymentsToAcquireIntangibleAssets | Payments to Acquire Intangible Assets | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | PaymentsToAcquireInvestments | Payments to Acquire Investments | USD | 0 | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001096906-19-000361 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 500,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.01 | 2020-09-30 | 2020 | Q3 | 10-Q/A | 2020-11-09 | 0001811884-20-000018 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 5.00M | 2020-09-30 | 2020 | Q3 | 10-Q/A | 2020-11-09 | 0001811884-20-000018 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2020-09-30 | 2020 | Q3 | 10-Q/A | 2020-11-09 | 0001811884-20-000018 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2020-09-30 | 2020 | Q3 | 10-Q/A | 2020-11-09 | 0001811884-20-000018 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2020-09-30 | 2020 | Q3 | 10-Q/A | 2020-11-09 | 0001811884-20-000018 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 418,000 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001096906-16-001451 | |
| us-gaap | ProceedsAndExcessTaxBenefitFromSharebasedCompensation | Proceeds and Excess Tax Benefit from Share-based Compensation | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001096906-20-000111 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 129,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | ProceedsFromNotesPayable | Proceeds from Notes Payable | USD | 0 | 2013-01-01 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 |
| us-gaap | ProceedsFromSaleOfAvailableForSaleSecurities | Proceeds from Sale of Available-for-sale Securities | USD | 74,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-14 | 0001096906-19-000100 |
| us-gaap | ProceedsFromSaleOfBuildings | Proceeds from Sale of Buildings | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-26 | 0001811884-21-000004 |
| us-gaap | ProceedsFromSaleOfLongtermInvestments | Proceeds from Sale of Long-term Investments | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-26 | 0001811884-21-000004 |
| us-gaap | ProceedsFromSaleOfProductiveAssets | Proceeds from Sale of Productive Assets | USD | 27,000 | 2024-01-01 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-10 | 0001811884-24-000015 |
| us-gaap | ProceedsFromSaleOfPropertyPlantAndEquipment | Proceeds from Sale of Property, Plant, and Equipment | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ProductWarrantyAccrual | Standard and Extended Product Warranty Accrual | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | 8.08M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 35.25M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 10.02M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | ProvisionForDoubtfulAccounts | Accounts Receivable, Credit Loss Expense (Reversal) | USD | -414,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | RepaymentsOfNotesPayable | Repayments of Notes Payable | USD | 4.78M | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-06 | 0001096906-18-000127 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 450,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | 133.26M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 25.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 0 | 2021-04-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-06 | 0001811884-21-000012 |
| us-gaap | RoyaltyIncomeNonoperating | Royalty Income, Nonoperating | USD | 20,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | SalesRevenueNet | Revenue, Net (Deprecated 2018-01-31) | USD | 21.85M | 2018-01-01 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-09 | 0001096906-18-000445 |
| us-gaap | SellingAndMarketingExpense | Selling and Marketing Expense | USD | 2.05M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | SellingGeneralAndAdministrativeExpense | Selling, General and Administrative Expense | USD | 6.42M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 269,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments | USD | 0.325 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) | pure | 3.8 | 2012-01-01 | 2012-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.311 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.038 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised | shares | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares | 275,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 65,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (Deprecated 2011-01-31) | shares | 55,287 | 2013-01-01 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-12 | 0001096906-14-000293 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | shares | 700 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares | 24,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 16.74 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 121,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 | |
| us-gaap | SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price | USD/shares | 70.95 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 | |
| us-gaap | ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit | Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit | USD/shares | 49.18 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 |
| us-gaap | ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares | 48,485 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 | |
| us-gaap | ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares | 84,301 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 | |
| us-gaap | SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price | USD/shares | 74.56 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 | |
| us-gaap | ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit | USD/shares | 82.6 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 123.28M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | USD | 123.28M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 | |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-27 | 0001096906-26-000395 |
| us-gaap | StockOptionPlanExpense | Stock or Unit Option Plan Expense | USD | 269,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | StockRepurchasedAndRetiredDuringPeriodShares | Stock Repurchased and Retired During Period, Shares | shares | 48,905 | 2024-10-01 | 2024-11-11 | 2024 | Q3 | 10-Q | 2024-11-12 | 0001811884-24-000022 |
| us-gaap | StockRepurchasedAndRetiredDuringPeriodValue | Stock Repurchased and Retired During Period, Value | USD | -905,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | TaxBenefitFromStockOptionsExercised | Tax Benefit from Stock Options Exercised (Deprecated 2012-01-31) | USD | 175,000 | 2013-01-01 | 2013-03-31 | 2013 | Q1 | 10-Q | 2013-05-08 | 0001096906-13-000677 |
| us-gaap | TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense | Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-25 | 0001811884-22-000004 |
| us-gaap | TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent | Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent | USD | 698,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-26 | 0001811884-24-000009 | |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | USD | 4,000 | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K/A | 2023-03-28 | 0001811884-23-000008 |
| us-gaap | WeightedAverageNumberDilutedSharesOutstandingAdjustment | Weighted Average Number Diluted Shares Outstanding Adjustment | shares | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 3.18M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 3.18M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001096906-26-001742 |